Tags

Type your tag names separated by a space and hit enter

Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab. 2012 Nov; 14(11):1040-6.DO

Abstract

AIM

To assess blood glucose control over 24 h and the safety of teneligliptin 10 and 20 mg, a novel dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

METHODS

Ninety-nine patients were administered teneligliptin 10 or 20 mg or placebo before breakfast for 4 weeks in a randomized, double-blind, placebo-controlled, parallel-group study.

RESULTS

Both teneligliptin-treated groups showed significantly smaller 2-h postprandial glucose (2-h PPG), 24-h mean glucose and fasting plasma glucose values than the placebo group. The differences between the teneligliptin 10 mg and placebo groups in changes in 2-h PPG after each meal were -50.7 ± 7.8, -34.8 ± 9.2 and -37.5 ± 7.5 mg/dl at breakfast, lunch and dinner, respectively [least-squares (LS) means ± standard error (s.e.), all, p < 0.001]. The corresponding LS means ± s.e. for teneligliptin 20 mg versus placebo were -38.1 ± 7.8, -28.6 ± 9.2 and -36.1 ± 7.5 mg/dl, respectively (p < 0.001, p < 0.01, p < 0.001, respectively). Both doses of teneligliptin increased postprandial plasma active glucagon-like peptide-1 concentrations compared with placebo. The incidence of adverse events and drug-related adverse events was similar among groups. There were no hypoglycaemic symptoms or serious adverse events.

CONCLUSIONS

Once-daily teneligliptin improved blood glucose levels over 24 h without hypoglycaemia.

Authors+Show Affiliations

Internal Medicine, Medical Co. LTA PS Clinic, Fukuoka, Japan. takashi-eto@lta-med.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22776014

Citation

Eto, T, et al. "Effects of Once-daily Teneligliptin On 24-h Blood Glucose Control and Safety in Japanese Patients With Type 2 Diabetes Mellitus: a 4-week, Randomized, Double-blind, Placebo-controlled Trial." Diabetes, Obesity & Metabolism, vol. 14, no. 11, 2012, pp. 1040-6.
Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012;14(11):1040-6.
Eto, T., Inoue, S., & Kadowaki, T. (2012). Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes, Obesity & Metabolism, 14(11), 1040-6. https://doi.org/10.1111/j.1463-1326.2012.01662.x
Eto T, Inoue S, Kadowaki T. Effects of Once-daily Teneligliptin On 24-h Blood Glucose Control and Safety in Japanese Patients With Type 2 Diabetes Mellitus: a 4-week, Randomized, Double-blind, Placebo-controlled Trial. Diabetes Obes Metab. 2012;14(11):1040-6. PubMed PMID: 22776014.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. AU - Eto,T, AU - Inoue,S, AU - Kadowaki,T, Y1 - 2012/07/29/ PY - 2012/03/08/received PY - 2012/04/03/revised PY - 2012/07/02/accepted PY - 2012/7/11/entrez PY - 2012/7/11/pubmed PY - 2013/3/23/medline SP - 1040 EP - 6 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 14 IS - 11 N2 - AIM: To assess blood glucose control over 24 h and the safety of teneligliptin 10 and 20 mg, a novel dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. METHODS: Ninety-nine patients were administered teneligliptin 10 or 20 mg or placebo before breakfast for 4 weeks in a randomized, double-blind, placebo-controlled, parallel-group study. RESULTS: Both teneligliptin-treated groups showed significantly smaller 2-h postprandial glucose (2-h PPG), 24-h mean glucose and fasting plasma glucose values than the placebo group. The differences between the teneligliptin 10 mg and placebo groups in changes in 2-h PPG after each meal were -50.7 ± 7.8, -34.8 ± 9.2 and -37.5 ± 7.5 mg/dl at breakfast, lunch and dinner, respectively [least-squares (LS) means ± standard error (s.e.), all, p < 0.001]. The corresponding LS means ± s.e. for teneligliptin 20 mg versus placebo were -38.1 ± 7.8, -28.6 ± 9.2 and -36.1 ± 7.5 mg/dl, respectively (p < 0.001, p < 0.01, p < 0.001, respectively). Both doses of teneligliptin increased postprandial plasma active glucagon-like peptide-1 concentrations compared with placebo. The incidence of adverse events and drug-related adverse events was similar among groups. There were no hypoglycaemic symptoms or serious adverse events. CONCLUSIONS: Once-daily teneligliptin improved blood glucose levels over 24 h without hypoglycaemia. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/22776014/Effects_of_once_daily_teneligliptin_on_24_h_blood_glucose_control_and_safety_in_Japanese_patients_with_type_2_diabetes_mellitus:_a_4_week_randomized_double_blind_placebo_controlled_trial_ L2 - https://doi.org/10.1111/j.1463-1326.2012.01662.x DB - PRIME DP - Unbound Medicine ER -